OmniAb (OABI) Q2 2026 earnings review
Business Model Validated as Milestones Drop to the Bottom Line
OmniAb delivered a massive Q2, proving its long-term strategy works. Revenue surged 244% YoY to $13.4M, driven by major clinical advancements in its partnered pipeline. Most importantly, this top-line explosion required zero incremental operating expense. GAAP operating expenses were flat YoY at $20.1M, allowing the net loss to narrow by over 60%. While management raised full-year guidance for the second consecutive quarter, the nature of milestone payments implies a severe deceleration in the second half of the year.
🐂 Bull Case
Total costs and operating expenses remained completely flat YoY at $20.1M, while revenue more than tripled. The highly scalable infrastructure is functioning exactly as designed.
The partner portfolio grew to 110 partners and 425 programs. High-profile advancements, like J&J's JNJ-5322 moving to Phase 3, are triggering significant, high-margin milestone payouts today.
🐻 Bear Case
The newly raised FY26 revenue guidance ($32M-$36M) implies H2 revenue of roughly $6.2M at the midpoint. This represents a drastic drop from the $27.8M generated in H1.
Despite management framing xPloration as a high-margin proprietary consumables engine, the segment's gross margin compressed significantly this quarter as costs outpaced revenue growth.
⚖️ Verdict: 🟢
Bullish. OmniAb is successfully transitioning from a cash-burning R&D platform to a scalable milestone-and-royalty engine. The near-term volatility is outweighed by the clear validation of the underlying economics.
Key Themes
Clinical Advancements Triggering Milestones
Accelerating. The clinical maturation of partner programs is the primary engine behind the Q2 beat. J&J's trispecific antibody (JNJ-5322) leaped from Phase 1 to Phase 3, triggering major payouts. Merck KGaA also dosed the first patient in a Phase 3 trial for M9140. With 34 OmniAb-derived programs now in clinical development, the probability of frequent milestone triggers is rising.
Disciplined Cost Controls Protecting Cash
Stable. The company is actively protecting its balance sheet. Research and development expenses declined YoY ($9.6M vs $10.9M), and General and Administrative expenses dropped ($6.7M vs $7.7M). This discipline allows milestone payments to fall directly to the bottom line, preserving a $52.0M cash runway that significantly de-risks the path to profitability.
xPloration Platform Driving New Revenue Streams
Accelerating. The high-throughput single B-cell screening platform, xPloration, is gaining significant traction. Revenue hit $1.16M in Q2, nearly double the $0.61M from a year ago. The recent appointment of Amechi Nwachuku as COO specifically to manage xPloration operations signals an aggressive commercial push.
xPloration Margins Contradicting Narrative
Management consistently pitches xPloration as a highly accretive, high-margin consumables business. However, the data tells a different story: while Q2 xPloration revenue grew 91% YoY (to $1.16M), the cost of xPloration revenue surged 133% (to $0.61M). Segment gross margins compressed to 47% from 57% a year ago. If this scaling requires heavier hardware subsidies, the cash flow narrative breaks.
Macro Sensitivity: Biotech Funding Cycles
While OmniAb is insulated from direct clinical trial costs, it is entirely reliant on the health of its partners. Broader macroeconomic pressures, including sustained high interest rates and inflation, routinely strain the capital reserves of early-stage biotech clients. If partners delay trial initiations to conserve cash, OmniAb's milestone timeline will immediately push to the right.
Inherent Lumpiness Obscures Underlying Growth
Stable. The $13.4M in Q2 revenue looks phenomenal YoY, but it is purely episodic. OmniAb operates a business where financial results do not reflect smooth quarter-over-quarter demand, but rather the binary outcomes of partner lab results and regulatory filings. Investors must digest wild sequential swings without panicking or over-celebrating.
Other KPIs
Accelerating slightly. Grew from 107 at the end of Q1 and 100 a year ago. Adding net new partners is critical to offsetting the natural attrition that occurs in early-stage drug discovery.
Accelerating. Up from 409 in Q1 and 381 in Q2 2025. This expanding funnel mathematically increases the volume of potential future milestones and eventual royalty stacks.
Guidance
Decelerating. While management raised the full-year target, generating $27.8M in H1 implies only $4.2M to $8.2M left for the entire second half of the year. This represents a severe expected drop-off in milestone triggers for Q3 and Q4.
Stable. This was revised up slightly from the previous $50M-$55M range. With $25.5M spent in H1, the implied $27.5M midpoint for H2 indicates spend will remain highly controlled through the end of the year.
Stable. Raised from $33M-$38M. Starting from the current $52.0M base, this implies roughly $11M to $15M in cash burn during H2. Given the expected revenue dip in H2, this burn rate highlights the company's defensive posture.
Key Questions
H2 Milestone Visibility
Your revised guidance implies a massive drop in revenue from H1 to H2. Is this purely conservatism regarding timing, or do you have explicit knowledge that major clinical catalysts are weighted toward 2027?
xPloration Gross Margins
We saw cost of xPloration revenue grow significantly faster than xPloration sales this quarter. What is the steady-state gross margin target for this segment, and are you currently discounting hardware to drive consumable adoption?
Impact of the New COO
With the addition of Amechi Nwachuku as COO to focus on xPloration, what specific operational bottlenecks is he tasked with solving, and how should we measure his success over the next 12 months?